MitoSense is Supporting Targeting Mitochondria 2024
MitoSense will be sponsoring the 15th WMS Annual Meeting, Targeting Mitochondria 2024, on October 29-31 at DoubleTree by Hilton Berlin Ku'damm, Berlin, Germany.
About MitoSense
MitoSense, Inc. is a research and development company in the field of securing development of treatments for neurodegenerative diseases. With exclusively licensed technology to replenish the mitochondria in humans using Mitochondria Organelle Transplantation (MOT™️), the company, through its U.S. based research partner is initially focusing its efforts on treating ALS. MOT™️ may impact research for patients with Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases, none of which have a cure.
What do they do?
MitoSense uses a proprietary (patent pending) technique to replenish mitochondria to treat ALS. The technique has the potential to treat a wide range of indications including Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis and other neurodegenerative diseases. With experienced leadership in business, government, research, and medical, we have brought together a multidisciplinary team to help in the fight.
Talk at Targeting Mitochondria 2024:
Dr. Mark Kindy, U.S. Department of Veterans Affairs James A. Haley VA Hospital and University of South Florida will be presenting a major talk during the meeting in Berlin: "Mitochondrial Transplantation Mediates Improved Cellular Energy Metabolism, Restoration of Mitochondrial Function and Prevention of Cell Death". His team at the VA is collaborating with MitoSense.
In his talk Dr. Kindy will cover:
- Isolation and characterization of mitochondria
- Application of mitochondrial transplantation
- Reversal of cellular dysfunction
- Restoration of energy metabolism
MitoSense Website:
MitoSense is collaborating with Dr. Kindy.
